[go: up one dir, main page]

ZA200505400B - The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis - Google Patents

The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis

Info

Publication number
ZA200505400B
ZA200505400B ZA200505400A ZA200505400A ZA200505400B ZA 200505400 B ZA200505400 B ZA 200505400B ZA 200505400 A ZA200505400 A ZA 200505400A ZA 200505400 A ZA200505400 A ZA 200505400A ZA 200505400 B ZA200505400 B ZA 200505400B
Authority
ZA
South Africa
Prior art keywords
treatment
multiple sclerosis
estrogen receptor
receptor alpha
alpha modulators
Prior art date
Application number
ZA200505400A
Other languages
English (en)
Inventor
Elloso M Merle
Douglas C Harnish
Mitchell Robert
Steven J Adelman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200505400B publication Critical patent/ZA200505400B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200505400A 2003-01-06 2005-07-04 The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis ZA200505400B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43812303P 2003-01-06 2003-01-06

Publications (1)

Publication Number Publication Date
ZA200505400B true ZA200505400B (en) 2006-12-27

Family

ID=32713279

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200505400A ZA200505400B (en) 2003-01-06 2005-07-04 The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis

Country Status (14)

Country Link
US (1) US20040167112A1 (xx)
EP (1) EP1585507A2 (xx)
JP (1) JP2006515616A (xx)
KR (1) KR20050091058A (xx)
CN (1) CN1723013A (xx)
AU (1) AU2004204675A1 (xx)
BR (1) BRPI0406643A (xx)
CA (1) CA2512021A1 (xx)
EC (1) ECSP055950A (xx)
MX (1) MXPA05007317A (xx)
NO (1) NO20053156L (xx)
RU (1) RU2005125043A (xx)
WO (1) WO2004062653A2 (xx)
ZA (1) ZA200505400B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082322A1 (en) * 2004-10-09 2009-03-26 The Regents Of The University Of Michigan Gender Differences in Experimental Aortic Aneurysm Formation
WO2011014516A1 (en) * 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
JP6836829B2 (ja) * 2014-08-04 2021-03-03 日東電工株式会社 核内受容体リガンドを含む免疫誘導促進用組成物及びワクチン医薬組成物
JP2019524805A (ja) * 2016-08-12 2019-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 髄鞘再生療法
KR102817163B1 (ko) * 2022-08-04 2025-06-05 고려대학교 산학협력단 바제독시펜을 유효성분으로 포함하는 염증성 피부질환의 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
FI973235L (fi) * 1995-02-06 1997-08-05 Lilly Co Eli Menetelmä IL-6:n vaikutusten inhiboimiseksi
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
ATE367816T1 (de) * 2000-05-12 2007-08-15 Univ Oregon Health & Science Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Also Published As

Publication number Publication date
EP1585507A2 (en) 2005-10-19
US20040167112A1 (en) 2004-08-26
BRPI0406643A (pt) 2005-12-06
KR20050091058A (ko) 2005-09-14
MXPA05007317A (es) 2005-09-30
NO20053156D0 (no) 2005-06-28
JP2006515616A (ja) 2006-06-01
CN1723013A (zh) 2006-01-18
WO2004062653A3 (en) 2004-11-04
AU2004204675A1 (en) 2004-07-29
NO20053156L (no) 2005-09-08
CA2512021A1 (en) 2004-07-29
WO2004062653A2 (en) 2004-07-29
RU2005125043A (ru) 2006-01-27
ECSP055950A (es) 2006-01-16

Similar Documents

Publication Publication Date Title
TWI340738B (en) Modulators of the glucocorticoid receptor
GB2394894B (en) New use for pharmaceutical composition
PL371596A1 (en) Use of compounds that are effective as selective opiate receptor modulators
AU2003256923A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
GB0307918D0 (en) Therapeutic use
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL179462A0 (en) Use of the receptor gpr86
SG118222A1 (en) Lithographic apparatus
AU2003902443A0 (en) Shower apparatus
GB2392618B (en) Compositions for therapeutic use
AU2003215621A1 (en) Use of compatible solutes for inhibiting the release of ceramides
GB0223098D0 (en) Medicinal apparatus
ZA200505400B (en) The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
GB0324276D0 (en) Sanitary apparatus
HK1082673A (en) The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
GB0227279D0 (en) Shower apparatus
ZA200409972B (en) Massage pad for bath
AU2003226396A8 (en) Imidazolidine compounds as chemokine receptor modulators
AU2003300867A8 (en) Uses of the snorf207 receptor
GB2415379B (en) Methyl-ß-orcinolcarboxylate from lichen (everniasrum cirrhatum) for use for the treatment of cancer
GB0301096D0 (en) Holding apparatus for soap
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
GB2407081B (en) Apparatus for use
GB0220977D0 (en) Shower apparatus
TW543817U (en) Improvement of removable apparatus